Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody
Year: 2026
Type: article
Abstract: Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.
Source: Blood
Authors: Muhamed Baljevic, Peter Voorhees, Cesar Rodriguez, Anita D'Souza, Alfred Chung, Eben Isaac Lichtman, Hana Safah, Katja C Weisel, Ravi Vij, Hira Mian, Hila Magen, Emma Searle, John T. Mckay, Neha S. Korde, Saurabh Chhabra, Anders Svensson, Rajvineeth Kumar Pothacamury, Chetasi Talati, Carli Allendorf, Claudie Hecquet, Valerie Robinson, Aarif Ahsan, Shaji K. Kumar
Institutions: University of Arkansas for Medical Sciences, Atrium Health Wake Forest Baptist, Wake Forest University, Froedtert Hospital, Medical College of Wisconsin Cancer Center, University of California, San Francisco, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Our Lady of the Lake Regional Medical Center, University Medical Center Hamburg-Eppendorf, Washington University in St. Louis, McMaster University, Tel Aviv University, Sheba Medical Center, University of Manchester, The Christie NHS Foundation Trust, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Mayo Clinic in Arizona, AbbVie (United States), Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,500
OpenAlex ID: W7233893068
